# A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

> **NCT02232230** · — · COMPLETED · sponsor: **GenesisCare USA** · enrollment: 20 (actual)

## Conditions studied

- Castrate Refractory Metastatic Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Provenge

## Key facts

- **NCT ID:** NCT02232230
- **Lead sponsor:** GenesisCare USA
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2018-06-05
- **Final completion:** 2018-06-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02232230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02232230, "A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02232230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*